Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
1.3550
-0.0350 (-2.52%)
NASDAQ · Last Trade: Apr 2nd, 5:11 PM EDT

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ:ZNTL) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).
By Newman Ferrara LLP · Via Business Wire · August 19, 2024

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) (NASDAQ: ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ZNTL.
By Bronstein, Gewirtz & Grossman, LLC · Via Business Wire · August 13, 2024

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) (NASDAQ: ZNTL) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · August 1, 2024

Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis’ proprietary ADC platform technology.
By Immunome, Inc. · Via Business Wire · January 8, 2024

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (“Zentalis” or the “Company”). The investigations concern whether certain of the Zentalis’ officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company’s business practices.
By Newman Ferrara LLP · Via Business Wire · January 10, 2023
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30 years, researchers have been looking into the potential of vaccines to treat ovarian cancer. Vaccines are a promising future treatment for […]
Via FinancialNewsMedia · May 18, 2022